Search
Spotlight
CME Opportunities
CME Opportunities
Specialty
View More
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
News
OncClub
All Oncology News
OncClub
All Oncology News
Media
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Conferences
Conference Coverage
Conference Listing
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Partners
Publications
Resources
Consensus Viewpoints
OncLive App
Interactive Tools
Sponsored
Consensus Viewpoints
OncLive App
Interactive Tools
Sponsored
Biomarker Consortium
Subscribe
Search
Spotlight
CME Opportunities
Specialty
See All >
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Questions and Controversies in Treating Breast Cancer
EP. 1: FDA Approval of Ribociclib for Metastatic Breast Cancer
June 16th 2017
EP. 2: CDK4/6 Inhibitors for HR+ Metastatic Breast Cancer
June 16th 2017
EP. 3: Choosing Therapy for HR+ Metastatic Breast Cancer
June 16th 2017
EP. 4: Emerging CDK4/6-Targeted Therapy for Breast Cancer
June 16th 2017
EP. 5: Endocrine Resistance in HR+ Metastatic Breast Cancer
June 16th 2017
EP. 6: Sequencing in Hormone-Driven Metastatic Breast Cancer
June 16th 2017
EP. 7: PI3K Inhibitors for HR+ Metastatic Breast Cancer
June 16th 2017
EP. 8: Adjuvant Therapy for HER2-Driven Breast Cancer
June 16th 2017
EP. 9: Extended Adjuvant Therapy for HER2-Positive Breast Cancer
June 16th 2017
EP. 10: APHINITY Trial in HER2+ Breast Cancer
June 16th 2017
EP. 11: Pending FDA Approval of Neratinib in HER2+ Breast Cancer
June 16th 2017
EP. 12: Adjuvant Therapy for High-Risk HER2+ Breast Cancer
June 16th 2017
EP. 13: Triple-Positive Metastatic Breast Cancer
June 16th 2017
EP. 14: Brain Metastases in HER2-Positive Breast Cancer
June 16th 2017
EP. 15: Metastatic Triple-Negative Breast Cancer
June 16th 2017
EP. 16: BRCA-Mutated Triple-Negative Breast Cancer
June 16th 2017
EP. 17: PARP Inhibitors for BRCA-Mutated TNBC
June 16th 2017
EP. 18: Immunotherapy for Triple-Negative Breast Cancer
June 16th 2017
EP. 19: Final Thoughts on Progress in Breast Cancer Research
June 16th 2017
EP. 20: Options With CDK4/6 in HR+ Metastatic Breast Cancer
June 16th 2017
NEXT PAGE
<
1
2
>
PREVIOUS PAGE
x
